SCHEMBL26618992

SCHEMBL26618992

COC(=O)c1ccn(C)c(=O)c1C(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.50
KDM4E B2RXH2 6/20 0.44
NR4A2 P43354 1/20 0.44
ALDH1A1 P00352 5/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA3 P34903 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 3/20 0.40
TP53 P04637 2/20 0.40
TSHR P16473 1/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1400324 0.81 CA12 (0.57) BRD4KDM4EALDH1A1CA12CA1
SCHEMBL31186077 0.81 KDM4E (0.44) BRD4KDM4ENR4A2ALDH1A1CA12
SCHEMBL27373973 0.80 KDM4E (0.42) BRD4KDM4ENR4A2ALDH1A1CA12
SCHEMBL30323454 0.80 KDM4E (0.42) BRD4KDM4ENR4A2ALDH1A1CA12
SCHEMBL2284288 0.78 BRD4 (0.54) BRD4KDM4ENR4A2ALDH1A1CA1
SCHEMBL25072433 0.77 KDM4E (0.46) BRD4KDM4ENR4A2ALDH1A1CA12
SCHEMBL16418351 0.77 KDM4E (0.46) BRD4KDM4ENR4A2ALDH1A1CA12
SCHEMBL31519943 0.76 ALDH1A1 (0.48) BRD4KDM4ENR4A2ALDH1A1CA1
SCHEMBL11348001 0.75 CA1 (0.56) KDM4EALDH1A1CA12CA1CA2
SCHEMBL22729670 0.75 NR4A2 (0.53) BRD4KDM4ENR4A2ALDH1A1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214995-A1 CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-07-03 US disclosed
EP-4514793-A1 CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER Astrazeneca AB (SE) 2025-03-05 EP disclosed
WO-2023209084-A1 CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-11-02 WO disclosed
WO-2023209084-A1 CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-11-02 WO disclosed
WO-2023209088-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-11-02 WO disclosed
WO-2023209088-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214995-A1 CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, SDHA BRD4 936/4885KDM4E 2306/4885NR4A2 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.